Scilex Holding Company presented post-hoc analysis of the C.L.E.A.R. trial for SP-102 (SEMDEXA™) at the 27th Annual Meeting of the American Society of Interventional Pain Physicians (ASIPP). The presentation interpreted the clinical meaningfulness of SP-102's safety and efficacy for lumbosacral radicular pain (LRP).
The results demonstrated clinically meaningful separation between SP-102 and placebo across multiple within-subject endpoints, including NPRS Responder Analyses, ODI, and BPI Pain Interference. This trend was enhanced when considering the mITT population, which confirmed study drug receipt.
The formulation of SP-102 was designed to be a safer alternative to current off-label products, and its benefit-risk profile supports its potential as a much-needed therapy for LRP. The findings indicate strong potential for this novel non-opioid treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.